The biotech company ViroGates has announced several changes in its management and board structure in preparation for the commercial launch of its suPAR technology.
Several changes in ViroGates' management and board structure have been made to support the company's move into the challenging phase of commercializing its suPAR technology and following Ian Laquian's retirement from his position as CEO of ViroGates.
Laquian has been CEO of ViroGates since 2003, successfully taking the company through several investment rounds and overseeing the development of ViroGates' first product suPARnostic, but has decided to move his professional efforts towards new challenges.
Betina Macho has been appointed new CEO of ViroGates A/S. From her previous professional career Macho has an international background in pharma and biotech, with a strong focus in business operations.
- ViroGates has a brilliant technology base with an impressive potential to make a real difference for people's lives. Over the past few months I already had the opportunity to gain insight into ViroGates' technology, its current applications and further potential and it is an honour to now take on the position as CEO and drive ViroGates' commercial and technological development with the company's dedicated and idealistic team, says Betina Macho, CEO, ViroGates.
In addition to the appointment of Macho, changes in the internal structure are taking place. Mads Kjær, investor and board member of ViroGates A/S, has been appointed Vice Chairman with responsibility for all financial issues and corporate governance.
Kjær comments that he is pleased to take the position as Vice Chairman in Virogates and moreover he is happy that Macho is willing to take the position as CEO. It will secure that the company can continue its business operations uninterrupted.
For further information visit the ViroGates homepage.